Are 0.1% timolol-maleate eyedrops suitable for treating chronic glaucoma? (author's transl)

Klinische Monatsblätter für Augenheilkunde
D Dausch, K Schad

Abstract

On the basis of 47 patients with chronic open-angle glaucoma, the administration of 0.1% timolol-maleate eye-drops was investigated in the form of a controlled long-term study over a period of 56 weeks. It was found that in a remarkable proportion of chronic glaucoma cases, this low concentration had an adequate, long-term effect, reducing IOP by 24-27%. The results obtained give sufficient grounds for the assumption that in the initial stages of glaucoma, the 0.1% solution is just as effective as solutions of a higher concentration, provided that a satisfactory degree of responsiveness to timolol-maleate is present from the outset. The local and systemic side-effects are relatively slight and therefore also fewer than with higher concentrations. Since in over 50% of patients with chronic glaucoma, 0.1% timolol-maleate eye-drops reduce IOP adequately over a considerable period of time, the 0.1% solution is to be recommended at all events for the initial treatment of glaucoma patients.

Citations

May 30, 2019·Ecological Applications : a Publication of the Ecological Society of America·Hugo CayuelaThierry Kinet

Related Concepts

Polychemotherapy
Glaucoma
Maleates
Ophthalmic Solution
Propanolamines
Timoptol

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Archaeal RNA Polymerase

Archaeal RNA polymerases are most similar to eukaryotic RNA polymerase II but require the support of only two archaeal general transcription factors, TBP (TATA-box binding protein) and TFB (archaeal homologue of the eukaryotic general transcription factor TFIIB) to initiate basal transcription. Here is the latest research on archaeal RNA polymerases.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.